# Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

> **NCT02435992** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 1012 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** RPC1063
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02435992
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-17
- **Primary completion:** 2020-03-27
- **Final completion:** 2020-06-17
- **Target enrollment:** 1012 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435992, "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02435992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*